Text Size

Inflammatory Markers in Patients With Active Migraine Headaches

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
Westside Family Medical Center, P.C.
ClinicalTrials.gov Identifier:
NCT00471861
First received: May 8, 2007
Last updated: August 5, 2011
Last verified: February 2009
History of Changes
  Purpose

The purpose of this study is to determine whether C-Reactive Protein (CRP) is elevated in patients with active migraine headaches. Secondary goal is to determine whether other inflammatory markers, such as Calcitonin Gene Peptide (CGRP), Vasoactive Intestinal Polypeptide (VIP) or Substance P (SP) are elevated in patients having a migraine headache.


Condition
Migraine

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: Does Migraine As A Partly Inflammatory Disease Increase The Inflammatory Markers Of The Patient When Actively Having a Migraine?

Resource links provided by NLM:

MedlinePlus related topics: Headache Migraine
U.S. FDA Resources

Further study details as provided by Westside Family Medical Center, P.C.:

Enrollment: 30
Study Start Date: May 2007
Study Completion Date: February 2009
Detailed Description:

A random selection of patients both male and female from a primary care practice with a diagnosis of having migraine headaches will be enrolled. Thirty (30) patients will be recruited mainly from the primary care practice. Recruitment will include males and females aged 21-65. The patients who meet the inclusion criteria will be enrolled. The patients who do not have migraine headaches will also be enrolled and function as controls. Non-migraine patients will meet inclusion criteria 1, 2 and 3 and all of the exclusion criteria.

  Eligibility

Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Migraine

Criteria

Inclusion Criteria:

  1. Subjects must sign a written informed consent.
  2. Enrollment population would include males and females 21 years of age to 65 years of age.
  3. Non-migraine subjects will be allowed in the control group
  4. Have episodic migraine headaches
  5. Patients to satisfy the diagnosis of migraine headaches with aura, without aura or mixed.
  6. Must be able to differentiate migraine headaches from other headaches

Exclusion Criteria:

  1. Any medical condition in the opinion of the investigator that would make the subject unsuitable for enrollment.
  2. Basilar or hemiplegic migraine headaches.
  3. Pregnant woman or a nursing mother
  4. History (within 1 year) or current evidence of drug or alcohol abuse.
  5. More than 15 migraine headaches per month
  6. Chronic daily headaches
  7. Chronic use of NSAIDs
  8. Current participation in a research study or within the last 30 days.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00471861

Locations
United States, Michigan
Westside Family Medical Center, P.C.
Kalamazoo, Michigan, United States, 49009
Sponsors and Collaborators
Westside Family Medical Center, P.C.
GlaxoSmithKline
Investigators
Principal Investigator: Gary E Ruoff, MD Westside Family Medical Center, P.C.
  More Information

No publications provided

Responsible Party: Gary E. Ruoff, Westside Family Medical Center
ClinicalTrials.gov Identifier: NCT00471861     History of Changes
Other Study ID Numbers: 109944
Study First Received: May 8, 2007
Last Updated: August 5, 2011
Health Authority: United States: Institutional Review Board

Keywords provided by Westside Family Medical Center, P.C.:
Inflammatory Markers
Migraine

Additional relevant MeSH terms:
Migraine Disorders
Headache Disorders, Primary
Headache Disorders
 Brain Diseases
Central Nervous System Diseases
Nervous System Diseases

ClinicalTrials.gov processed this record on May 21, 2013